# Silica Corpora

## About

*In Silica Corpora we design the next generation of antibody therapeutics using generative AI. Our Platform MALI offers an unprecedented accuracy in antibody design, achieved through enormous sequence-based training datasets and exceptional capabilities for integrating project-specific in vitro data

- Verified: Yes

## Services

### Biotech Drug Discovery
- [AI-Driven Therapeutic Development](https://bilarna.com/services/biotech-drug-discovery/ai-driven-therapeutic-development)

### Antibody Therapeutics
- [De Novo Antibody Design](https://bilarna.com/services/antibody-therapeutics/de-novo-antibody-design)

## Frequently Asked Questions

**Q: How does AI improve antibody drug discovery?**
A: AI improves antibody drug discovery by enabling precise design and optimization of therapeutic antibodies. 1. Use AI models trained on vast amino acid sequence datasets to generate novel antibody candidates. 2. Apply discriminator modules to predict key antibody properties such as stability and immunogenicity. 3. Optimize candidates to meet specific therapeutic profiles using mutation predictions. 4. Map epitopes accurately without relying on 3D structures, enhancing target specificity. This approach accelerates discovery, reduces experimental workload, and increases the likelihood of successful drug candidates.

**Q: What are the key modules used in AI-driven antibody design?**
A: The key modules in AI-driven antibody design include: 1. Generator: Produces antibody candidates as amino acid sequences for heavy and light chains. 2. Discriminator: Predicts antibody properties such as developability, thermal stability, solubility, self-aggregation, and immunogenicity. 3. Optimizer: Mutates candidates to align with specific target product profiles, enhancing desired characteristics. 4. Ep-Mapper: Accurately predicts epitopes on antigens independently of 3D structure, covering linear and conformational epitopes. These modules work together to generate, evaluate, optimize, and map antibodies efficiently.

**Q: How can AI platforms integrate project-specific data in drug development?**
A: AI platforms integrate project-specific data in drug development by: 1. Utilizing modular systems that accept amino acid sequences and in vitro data unique to each project. 2. Fine-tuning AI models with small, project-specific datasets to improve prediction accuracy. 3. Combining historical and current project data to accelerate discovery and uncover new insights. 4. Adapting candidate antibodies to meet precise target product profiles based on integrated data. This synergy enhances efficiency, reduces reliance on large datasets, and supports adaptive workflows without disrupting existing laboratory processes.

## Links

- Profile: https://bilarna.com/provider/silica-corpora
- Structured data: https://bilarna.com/provider/silica-corpora/agent.json
- API schema: https://bilarna.com/provider/silica-corpora/openapi.yaml